視神經脊髓炎治療市場報告：趨勢、預測和競爭分析（至2035年）

視神經脊髓炎治療藥物市場

全球視神經脊髓炎治療市場前景廣闊，急性發作期治療和緩解期維持治療市場均蘊藏巨大機會。預計全球視神經脊髓炎治療市場規模將從2027年的544億美元成長至2035年的711億美元，2027年至2035年的年複合成長率（CAGR）為3.1%。推動市場成長的主要因素包括視神經脊髓炎盛行率的上升、對標靶治療需求的成長以及對自體免疫疾病治療的日益重視。

• 根據 Lucintel 的預測，在各種治療類型中，由於免疫療法專注於標靶緩解疾病，預計在預測期內將實現高速成長。
• 就適應症而言，急性視神經脊髓炎頻譜障礙患者的發病率正在增加，因此預計在預測期內「急性癲癇發作」類別將出現更高的成長。
• 從區域來看，亞太地區（APAC）預計將在預測期內呈現最高的成長率，這主要得益於各種疾病診斷率的提高和神經系統疾病護理覆蓋範圍的擴大。

視神經脊髓炎治療市場的新趨勢

從2025年到2027年，視神經脊髓炎市場預計將發生變化，重點將轉向預防復發和長期殘疾管理。目前，獲得監管機構批准的生物製藥是推動這一市場轉變的主要因素。其他影響市場的因素包括診斷方法的普及和保險報銷。根據Lucintel預測，市場對生物製藥的需求預計將持續成長。

• 標靶生技藥品：生技藥品的主要差異在於補體系統抑制劑、IL-6抑制劑和B細胞抑制劑。在2020年代，所有這三種作用機制的生技藥品均已獲得監管部門批准。新型生技藥品的製劑研發將基於這些作用機制。
• 維持治療：特別是，鑑於數據顯示生物製藥可以減輕視神經脊髓炎患者的損傷，治療的重點將是預防復發。
• 基於生物標記的診斷：生物標記在視神經脊髓炎診斷中的作用將繼續發揮，區分針對 MOG 和 AQP4 的自身抗體將有助於對患者進行更適當的分類。
• 給藥方式更便捷：皮下和靜脈給藥為需要頻繁就醫的傳統治療方案提供了替代方案。 2020年沙曲珠單抗的核準確立了低治療頻率的治療模式。居家靜脈給藥的便利性和更長的給藥間隔預計將影響治療方案的選擇。
• 經濟負擔：高價藥物之間日益激烈的競爭促使支付方要求提供更有力的證據，例如基於結果的研究和預算支出合理性證明（JNS），以支持藥物訂購。如果沒有證據顯示能夠降低醫療成本的經濟負擔，製藥商將無法充分證明報銷的合理性。

視神經脊髓炎的治療市場正從急性期治療轉向長期治療。最初用於治療該疾病的藥物作用機制獨特，但高成本。未來五年，如果製藥公司能夠提高治療的永續性和便利性，尤其是在生物標記開發方面取得進展，則有望擴大市場佔有率。

視神經脊髓炎（NMO）治療市場的最新趨勢

由於新型生物製藥的出現和藥品標籤法規的變更，視神經脊髓炎 (NMO) 治療市場的競爭日益激烈。預計在 2025 年至 2027 年間，將有新藥上市，適應症也將擴大，同時私募股權和創業投資也將增加對候選藥物研發的投資。在 NMO 治療市場，能夠透過降低復發率和提高使用便利性來改變疾病進程的藥物，有望獲得競爭優勢。

• 監管變化：2025年，「Apprisna」（inebilizumab）的監管規定進行了調整，使其適應症範圍從視神經脊髓炎譜系疾病（NMOSD）擴展至全身型重症肌無力（GMG）。隨著醫療專業人員對該藥物的使用經驗和熟練程度的提高，其在NMO治療市場的佔有率有望進一步擴大。
• 基於B細胞清除的競爭：到2025年，Horizo​​n公司已累積了超過1000名患者使用Applizna的經驗。未來五年，競爭對手預計也將致力於提高療效持續時間和延長給藥間隔。
• 擴大兒童適應症：2021年7月，FDA核准羅氏公司的恩斯普林（Ensprine）用於12歲以上兒童患者。預計其他NMO藥物也將迎來類似的監管調整，這有望促進兒童患者的治療，並延緩其殘疾的進展。
• 研發管線多元化：到2025年，多個新的補體標靶抑制劑和標靶抑制劑研發管線已取得進展。此外，一些新型藥物研發計畫專注於設計每月一次或更少給藥的療法。如果臨床試驗數據證實，與目前的標準療法相比，標靶B細胞和IL-6R通路療法在預防復發和提​​高安全性方面具有更佳效果，則此類療法可能會面臨競爭。
• 准入夥伴關係：到2025年，包括UPLIZNA在內的更多生物製藥公司在產品上市時採用了病患支援和專科藥局模式。這兩種服務的結合提高了治療的可近性，並對醫療保健成本產生了積極影響。預計其他支付方也將採取類似策略，以更好地控制醫療保健成本。

未來幾年，隨著基於IL-6R和C5通路以及B細胞清除療法的新型療法獲得監管部門批准，視神經脊髓炎（NMO）治療市場的競爭預計將進一步加劇。能夠提供更優數據（尤其是在兒童）以及獨家進入許可權證明的公司，預計將擴大其市場佔有率。

目錄

第1章執行摘要

第2章 市場概覽

• 背景與分類
• 供應鏈

第3章 市場趨勢與預測分析

• 宏觀經濟趨勢與預測
• 產業促進因素與挑戰
• PESTLE分析
• 專利分析
• 法規環境

第4章：全球視神經脊髓炎治療市場：依類型分類

• 吸引力分析：按類型
• 糖皮質激素
• 免疫療法
• 其他

第5章：全球視神經脊髓炎治療市場：依應用分類

• 吸引力分析：依目的
• 急性癲癇發作
• 復發預防治療

第6章 區域分析

第7章：視神經脊髓炎治療藥物的北美市場

• 北美視神經脊髓炎治療市場：按類型分類
• 北美視神經脊髓炎治療市場：依應用領域分類
• 美國視神經脊髓炎治療藥物市場
• 加拿大視神經脊髓炎治療藥物市場
• 墨西哥視神經脊髓炎治療藥物市場

第8章：視神經脊髓炎治療藥物的歐洲市場

• 歐洲視神經脊髓炎治療市場：依類型分類
• 歐洲視神經脊髓炎治療市場：依應用領域分類
• 德國視神經脊髓炎治療藥物市場
• 法國視神經脊髓炎治療藥物市場
• 義大利視神經脊髓炎治療藥物市場
• 西班牙視神經脊髓炎治療藥物市場
• 英國視神經脊髓炎治療藥物市場

第9章：視神經脊髓炎治療藥物的亞太市場

• 亞太地區視神經脊髓炎治療市場：依類型分類
• 亞太地區視神經脊髓炎治療市場：依應用領域分類
• 中國視神經脊髓炎治療藥物市場
• 印度視神經脊髓炎治療藥物市場
• 日本視神經脊髓炎治療藥物市場
• 韓國視神經脊髓炎治療市場
• 印尼視神經脊髓炎治療藥物市場

第10章：世界其他地區視神經脊髓炎治療藥物市場

• 視神經脊髓炎治療的其他區域市場：按類型分類
• 其他視神經脊髓炎治療的區域市場：按應用
• 中東地區視神經脊髓炎治療藥物市場
• 南美洲視神經脊髓炎治療市場
• 非洲視神經脊髓炎治療藥物市場

第11章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析
• 市佔率分析

第12章 機會與策略分析

• 價值鏈分析
• 成長機會分析
• 新趨勢：全球視神經脊髓炎治療市場
• 戰略分析

第13章：價值鏈中關鍵企業的公司概況

• 競爭分析概述
• Pfizer
• Fresenius
• Teva
• Sandoz
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL

第14章附錄

Neuromyelitis Optica Drug Market

The future of the global neuromyelitis optica drug market looks promising with opportunities in the acute attack and remission prophylactic treatment markets. The global neuromyelitis optica drug market is expected to reach an estimated $71.1 billion by 2035 from $54.4 billion in 2027 with a CAGR of 3.1% from 2027 to 2035. The major drivers for this market are the increasing prevalence of neuromyelitis optica, the rising demand for targeted drug therapies, and the growing focus on autoimmune disease treatments.

• Lucintel forecasts that, within the type category, immunotherapy is expected to witness higher growth over the forecast period due to immunotherapy focuses on targeted disease modification.
• Within the application category, acute attack is expected to witness higher growth over the forecast period due to increasing incidence of patients experiencing acute neuromyelitis optica spectral disorder attacks.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to greater diagnosis rates of various diseases and expanding access to neurology care.

Emerging Trends in Neuromyelitis Optica Drug Market

The period from 2025 to 2027 will see changes in the neuromyelitis optica market as the focus shifts to preventing relapses and addressing long-term disability. Currently, biologics that are approved by regulatory agencies are the main drivers of changes in the market. Other factors that impact the market include the availability of diagnostics and reimbursement. According to Lucintel, the market will continue to show a demand for biologics.

• Targeted Biologics: The main areas of differentiation in biologics are inhibitors of the complement system, IL-6, and B cells. During the 2020s, there was regulatory approval for biologics with all three mechanisms. Prescribing and developing new biologics will be based on these mechanisms.
• Maintenance Therapy: The focus of therapy will be on preventing relapses, especially because of the data showing that biologics reduce the disability of patients with neuromyelitis optica.
• Biomarker Guided Diagnosis: The role of biomarkers in diagnosing neuromyelitis optica will continue, and better patient classification will be possible with the differentiation of autoantibodies against MOG and AQP4.
• Greater Convenience for Administration: Subcutaneous and Infusion routes of administration are alternative options to the frequent, hospital based, care methods. The approval of satralizumab in 2020, established a lower frequency of care model. The ease of home infusion, and prolonged time between infusions, will influence the choice of treatment.
• Economic Burden: Increased competition among high cost drugs has resulted in payers requiring greater evidence, such as outcome based research and justification for budget spending (JNS) to support drug sequencing. Without evidence, showing a savings in health care economic burden, manufacturers will have a limited case for reimbursement.

The market for treatment of Neuromyelitis optica is shifting from acute treatment to long term treatment. The first class of drugs to treat the condition, have an unusual mechanism of action and high costs. In the next five years, manufacturers may gain market share if they improve the longevity and convenience of treatment, particularly if accompanied by the development of biomarkers.

Recent Developments in the Neuromyelitis Optica Drug Market

The competition for a market share of neuromyelitis optica (NMO) drugs has increased, with new biologics and regulatory changes to drug labels. Between 2025 and 2027, we expect the introduction of new drugs and the extension of labels, and the private equity and venture capital investment that will provide funding for the development of drug candidates. In the neuromyelitis optica drug market, the ability of a drug to modify the course of the disease by decreasing the frequency of relapses and improving convenience of use will create a competitive edge.

• Regulatory Changes: Uplizna's (inebilizumab) regulatory changes to allow its use in generalized myasthenia gravis (GMG) in 2025 expanded its indication beyond NMOSD. As experience and comfort level of healthcare personnel with a drug increases, it may be easier to gain market share in the NMO drug market.
• Competition Based on B-cell Depletion: By 2025, Horizon had experience using Uplizna in over 1,000 patients. We expect a similar focus in the next five years by competitors on improving the durability of the treatment effect and extending the time between treatments.
• Extension To Pediatric Use: In July 2021, the FDA approved Roche's Enspryng for the treatment of pediatric patients 12 years and older. We expect similar regulatory changes for other drugs in the NMO market, encouraging the treatment of pediatric patients, and potentially modifying the wheel of disability.
• Diversification of Pipelines: Several new complement and targeted inhibitor pipelines progressed in 2025. Also, some new drug development programs focused on designing therapies that would be administered monthly or less. If data from clinical trials support better relapse control and/or safer outcomes compared to current standard of care, B-cell and IL-6R pathway therapies may face competition.
• Access Partnerships: More biopharmaceutical companies adopted patient support and specialty pharmacy models for product launches in 2025, including UPLIZNA. The combination of the two services improved access to treatment and positive impacts on the cost of healthcare. Other payer organizations are expected to adopt similar strategies to better control the cost of care.

More competition is expected for therapies for neuro-myelitis optica (NMO) in the coming years as new therapies based on IL-6R and C5 pathways and B-cell depletion gain regulatory approval. Companies that provide better data, especially pediatric data and evidence of exclusive access, are expected to capture larger shares of the market.

Strategic Growth Opportunities in the Neuromyelitis Optica Drug Market

Certain trends in the neuromyelitis optica drug market between 2024 and 2026 will provide growth opportunities due to increasing prevention of relapses and improvements in diagnosis. Our analysis aligns with industry trends. Biologics will continue to face competition. Demand will grow for simpler methods of B-cell depletion.

• Other Indications: The Food and Drug Administration's approval of Uplizna for generalized myasthenia gravis in June 2025 allows the use of inebilizumab for two indications. Over the next three to five years, other indications of myasthenia gravis and other autoimmune indications may be considered.
• Long-acting: The long-acting nature of ENSPRYNG (every 4 weeks after loading) compared to other therapies may improve adherence and preferability. Home-based care may also lead payers to cover the therapy. Convenient dosing may positively impact pricing.
• Paediatric: Limited evidence has focused on children. The 2025 framework encouraged the development of safe and effective biologics for children and may facilitate studies in this area.
• New Market Development: Asia offers a lot of potential with further development of regional specialty diagnosis and reimbursement. Japan, with a 2025 national health estimate of ¥48 trillion, has the financial means to cover the cost of specialty medicines, and, with local alliances, access barriers may be removed.
• Personalized Medicine: Availability of anti-AQP4 antibodies may help select patients that could benefit from therapy and may assist in ruling out patients that are unlikely to benefit from therapy, thereby facilitating development of other strategies for those patients. The data from major laboratory studies in 2025 indicated that AQP4 assays had an analyte specificity of 90% or greater.

In the case of anti-AQP4 antibody therapies, the main driver for increased sales may be the expansion of the patient population treated, rather than the launch of additional therapies. The key to success in this area may be integrating real-world evidence to influence the decisions of payers. There may be opportunities to expand the product's value, particularly through collaborative alliances and the application of biomarkers.

Neuromyelitis Optica Drug Market Drivers and Challenges

Neuromyelitis optica is poised for growth as a result of major advancements in biologics, greater awareness and education, and appropriate healthcare investment and reform. Regulatory reform, increased awareness and education, and better diagnosis of neuromyelitis optica will remain the main factors driving the growth of the pharmaceutical industry for neuromyelitis optica. Lucintel predicts that ongoing and future biotechnology advancements and favorable reforms will positively impact the neuromyelitis optica market in the future.

The factors responsible for driving this market include:

• Increased Awareness and Training of Healthcare Professionals: As the recognition of NMOSD increases, so does the instruction of healthcare professionals regarding the antibody testing and treatment of NMOSD. Earlier referrals and the validation of Aqu and anti-MOG antibodies have aided in the identification and reduced the misdiagnosis of NMOSD. Furthermore, biologics for the treatment of NMOSD received approval and entered the market. It is anticipated that in the following three to five years, healthcare professionals' and the general public's increased awareness regarding NMOSD would lead to an increase in the diagnosis and treatment of the condition.
• Therapy Options: The development of new complement, IL-6, and B-cell targeted therapies poses the opportunity to decrease disease activity and relapses, compared to traditional broad-spectrum immunosuppression. These targeted treatments may enable precision medicine strategies for the management of relapsing MS. Approved, first-in-class MS therapies based on mechanism, rather than target, continue to gain market traction and give physicians more options. By 2025, the leading markets will have multiple options, and physicians will be able to make more informed treatment choices. We anticipate continuous research and development of MS therapies based on appropriate mechanisms over the next 5 years.
• Diagnostics: The increasing availability of aquaporin-4 antibody testing, as well as other advanced medical diagnostics and imaging, is facilitating the detection of NMOSD. Early diagnosis and treatment are critical in order to prevent attacks from permanently damaging the optic nerves, spinal cord, and other areas of the central nervous system. The use of aquaporin-4 antibody testing, in combination with other advanced diagnostics, enabled NMOSD physicians to make a definitive diagnosis and select the most appropriate treatment for their patients in 2025. Within the next several years, we anticipate continued advancements in diagnostics, digital health, and other emerging technologies, thereby facilitating the early detection of NMOSD and other neurological disorders.
• Clinical Trials: The recognition of NMOSD as a distinct entity has encouraged the development of therapies focused on reducing relapses and disability accumulation. Advancements in diagnostics, and the development of disease activity biomarkers, have allowed the MS and NMOSD fields to investigate relapses, disability, and other outcome measures associated with MS and NMOSD. 2025 represented a pivotal year for clinical research focusing on MS and other neuroinflammatory and autoimmune disorders. Rigorous standard and lengthy extension studies will remain the basis for the clinical evaluation of novel MS therapies over the next 5 years. We expect the emerging evidence to ultimately change disease treatments and expand indications.
• Premium Value and Preventive Treatment: When preventing relapses, the use of biologics can be cost-effective. Preventing a single severe relapse can reduce the cost of caring for a patient. This is especially true for patients with severe forms of the condition and patients with frequent relapses. As of 2025, there were several biologics available to prevent relapses for NMOSD. There were various routes of administration including IV and injectable. There was further evidence to suggest that in the next few years, biologics would be administered in settings outside of a hospital. It is expected that evidence supporting the use of biologics would improve along with access; however, this would depend on the outcome of cost-effectiveness analyses.

The challenges facing this market include:

• High Cost of Biologics: Biologics are expensive to manufacture. The high costs are passed on to patients and health care systems. It is not uncommon for patients to not receive treatment due to costs and system constraints. In 2025, biologics for the treatment of NMOSD were specialty medicines. The use of NMOSD biologics requires prior authorization by insurance companies. It is expected that during the next five years, biosimilar biologics will be developed and marketed, and many will be priced lower than the originator biologics.
• Lack of A Broad Patient Population: It is difficult for biopharmaceutical companies to meet their business objectives because NMOSD is a rare disease. Biopharmaceutical companies face challenges in recruiting and enrolling sufficient patients to conduct adequate and comparative post-market clinical evaluation studies. Small patient populations make it difficult for companies to serve broad geographic markets and increase their distribution. In 2025, many of the ongoing biologics clinical trials for the treatment of NMOSD recruited fewer than 500 patients. Small patient populations increase the costs of clinical research and limit the number of clinical studies that can be conducted. During the next five years, it is expected that international research and clinical collaboration will be the basis for the development of new therapies for NMOSD.
• Safety and Reimbursement Risks: Long-term immunosuppression always puts the patient at risk for infection and may impact vaccination. While trying to prevent a relapse, the physician considers many factors including the health of the patient and whether the patient is pregnant. In 2025, the four main targeted biologics in use at the time were expected to require different safety measurements and monitoring. There may also be changing payer preferences, safety concerns, and evidence. Over the next few years it is expected that the biologics used to treat neuromyelitis optica may see a shift in how long they are used and the Biologic that quickly gains market share.

It is expected that in the next 3-5 years, the drug market for treatment of neuromyelitis optica will be shifted from broad immunosuppressive therapies to more targeted biologics. There should be better diagnostics, and a more supportive regulatory environment. There should also be increasing off label use of the drugs to treat neuromyelitis optica, especially if better control of relapsing remitting symptoms is achieved. Better control of neuromyelitis optica symptoms is expected; however, several barriers may restrict the use of these treatments including high prices, especially in countries where there is not a large neuromyelitis optica patient population.

List of Neuromyelitis Optica Drug Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neuromyelitis optica drug market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neuromyelitis optica drug market companies profiled in this report include-

• Pfizer
• Fresenius
• Teva
• Sandoz
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL

Neuromyelitis Optica Drug Market by Segment

The study includes a forecast for the global neuromyelitis optica drug market by type, application, and region.

Neuromyelitis Optica Drug Market by Type [Value ($B) from 2019 to 2035]:

• Glucocorticoids
• Immunotherapies
• Others

Neuromyelitis Optica Drug Market by Application [Value ($B) from 2019 to 2035]:

• Acute Attack
• Remission Prophylactic Treatment

Neuromyelitis Optica Drug Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neuromyelitis Optica Drug Market

Competition in the neuromyelitis optica drug market is set to increase with broader use of antibody therapies. In 2025, changes to the regulatory landscape broadened the availability of innovative therapies. Pharmaceutical companies have strategic plans to protect and extend the market presence of their neuromyelitis optica drugs. Other plans focus on the local marketing and reimbursement of therapies. Additionally, companies sponsor and perform clinical studies to gain and maintain market presence. According to Lucintel, these strategies will substantially alter market competitors between 2022 and 2027.

• United States: The U.S. Food and Drug Administration (FDA) approved Horizon Therapeutics' antibody, Uplizna (inebilizumab-cdon), in June 2025, to treat patients with generalized myasthenia gravis (MG). Previously, the antibody was approved to treat neuromyelitis optica spectrum disorder (NMOSD) in 2020. With the recent and more recent approvals, it is anticipated that Uplizna and other antibodies in the Horizon Therapeutics' platform will gain commercial and prescribing physician experience in the United States. This will likely benefit other commercialization efforts for NMOSD-related indications.
• China: Currently, the only biologic therapy for the treatment of NMOSD in China is Roche's Enspryng (Satralizumab). However, other Chinese biopharmaceutical companies are actively involved in the research and development of similar therapies. It is expected that in the next 3-5 years, the availability of a greater number of local therapies will increase, thereby improving competition in this market.
• Germany: Uplizna (inebilizumab) is approved by the European Commission for use with adult patients with generalized myasthenia gravis (GMG) with anti-AChR or anti-MuSK antibodies. It is also approved for use with patients with neuromyelitis optica spectrum disorder (NMOSD). GMG is a disease that affects neuromuscular transmission, resulting in generalized muscle weakness. Myasthenia gravis is a rare disease that affects the autonomic nervous system and is associated with fatigue. Anti-AChR antibodies are present in 80 to 90% of patients with myasthenia gravis. EU approval opens the potential market for Uplizna and may positively influence the opinion of German neurologists during the next 3 to 5 years.
• India: Roche has made satralizumab available in India for patients with NMOSD through its specialty care business, and continues to build its biologic infusion network. Satralizumab is a monoclonal antibody that modulates the inflammatory response and has shown positive clinical effects in patients with NMOSD. Positive changes in the private pharmacy and logistics sector may enhance the availability of specialty care and accelerate the time to initiation of specialty care in the next 3 to 5 years.
• Japan: Chugai Pharmaceutical is the only company with an approved and commercially available NMOSD treatment in Japan. Enspryng is a subcutaneous autoantibody treatment. Due to a limited number of available biologic treatments for NMOSD, Enspryng is expected to retain its market position during the next 3 to 5 years.

Features of the Global Neuromyelitis Optica Drug Market

• Market Size Estimates: neuromyelitis optica drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: neuromyelitis optica drug market size by type, application, and region in terms of value ($B).
• Regional Analysis: neuromyelitis optica drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the neuromyelitis optica drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neuromyelitis optica drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neuromyelitis optica drug market by type (glucocorticoids, immunotherapies, and others), application (acute attack and remission prophylactic treatment), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Neuromyelitis Optica Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Glucocorticoids : Trends and Forecast 2019 to 2035
• 4.4 Immunotherapies : Trends and Forecast 2019 to 2035
• 4.5 Others : Trends and Forecast 2019 to 2035

5. Global Neuromyelitis Optica Drug Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Acute Attack : Trends and Forecast 2019 to 2035
• 5.4 Remission Prophylactic Treatment : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Neuromyelitis Optica Drug Market by Region

7. North American Neuromyelitis Optica Drug Market

• 7.1 Overview
• 7.2 North American Neuromyelitis Optica Drug Market by Type
• 7.3 North American Neuromyelitis Optica Drug Market by Application
• 7.4 The United States Neuromyelitis Optica Drug Market
• 7.5 Canadian Neuromyelitis Optica Drug Market
• 7.6 Mexican Neuromyelitis Optica Drug Market

8. European Neuromyelitis Optica Drug Market

• 8.1 Overview
• 8.2 European Neuromyelitis Optica Drug Market by Type
• 8.3 European Neuromyelitis Optica Drug Market by Application
• 8.4 German Neuromyelitis Optica Drug Market
• 8.5 French Neuromyelitis Optica Drug Market
• 8.6 Italian Neuromyelitis Optica Drug Market
• 8.7 Spanish Neuromyelitis Optica Drug Market
• 8.8 The United Kingdom Neuromyelitis Optica Drug Market

9. APAC Neuromyelitis Optica Drug Market

• 9.1 Overview
• 9.2 APAC Neuromyelitis Optica Drug Market by Type
• 9.3 APAC Neuromyelitis Optica Drug Market by Application
• 9.4 Chinese Neuromyelitis Optica Drug Market
• 9.5 Indian Neuromyelitis Optica Drug Market
• 9.6 Japanese Neuromyelitis Optica Drug Market
• 9.7 South Korean Neuromyelitis Optica Drug Market
• 9.8 Indonesian Neuromyelitis Optica Drug Market

10. ROW Neuromyelitis Optica Drug Market

• 10.1 Overview
• 10.2 ROW Neuromyelitis Optica Drug Market by Type
• 10.3 ROW Neuromyelitis Optica Drug Market by Application
• 10.4 Middle Eastern Neuromyelitis Optica Drug Market
• 10.5 South American Neuromyelitis Optica Drug Market
• 10.6 African Neuromyelitis Optica Drug Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Neuromyelitis Optica Drug Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Pfizer
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Fresenius
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Teva
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sandoz
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Intas
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Gyjtrs
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 NANG KUANG
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Tianjin Kingyork
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Baxter
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 CSL
  • Company Overview
  • Neuromyelitis Optica Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us

List of Figures

• Figure 1.1: Trends and Forecast for the Global Neuromyelitis Optica Drug Market
• Figure 2.1: Usage of Neuromyelitis Optica Drug Market
• Figure 2.2: Classification of the Global Neuromyelitis Optica Drug Market
• Figure 2.3: Supply Chain of the Global Neuromyelitis Optica Drug Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 3.19: Driver and Challenges of the Neuromyelitis Optica Drug Market
• Figure 4.1: Global Neuromyelitis Optica Drug Market by Type in 2019, 2026, and 2035
• Figure 4.2: Trends of the Global Neuromyelitis Optica Drug Market ($B) by Type
• Figure 4.3: Forecast for the Global Neuromyelitis Optica Drug Market ($B) by Type
• Figure 4.4: Trends and Forecast for Glucocorticoids in the Global Neuromyelitis Optica Drug Market (2019-2035)
• Figure 4.5: Trends and Forecast for Immunotherapies in the Global Neuromyelitis Optica Drug Market (2019-2035)
• Figure 4.6: Trends and Forecast for Others in the Global Neuromyelitis Optica Drug Market (2019-2035)
• Figure 5.1: Global Neuromyelitis Optica Drug Market by Application in 2019, 2026, and 2035
• Figure 5.2: Trends of the Global Neuromyelitis Optica Drug Market ($B) by Application
• Figure 5.3: Forecast for the Global Neuromyelitis Optica Drug Market ($B) by Application
• Figure 5.4: Trends and Forecast for Acute Attack in the Global Neuromyelitis Optica Drug Market (2019-2035)
• Figure 5.5: Trends and Forecast for Remission Prophylactic Treatment in the Global Neuromyelitis Optica Drug Market (2019-2035)
• Figure 6.1: Trends of the Global Neuromyelitis Optica Drug Market ($B) by Region (2019-2026)
• Figure 6.2: Forecast for the Global Neuromyelitis Optica Drug Market ($B) by Region (2027-2035)
• Figure 7.1: Trends and Forecast for the North American Neuromyelitis Optica Drug Market (2019-2035)
• Figure 7.2: North American Neuromyelitis Optica Drug Market by Type in 2019, 2026, and 2035
• Figure 7.3: Trends of the North American Neuromyelitis Optica Drug Market ($B) by Type (2019-2026)
• Figure 7.4: Forecast for the North American Neuromyelitis Optica Drug Market ($B) by Type (2027-2035)
• Figure 7.5: North American Neuromyelitis Optica Drug Market by Application in 2019, 2026, and 2035
• Figure 7.6: Trends of the North American Neuromyelitis Optica Drug Market ($B) by Application (2019-2026)
• Figure 7.7: Forecast for the North American Neuromyelitis Optica Drug Market ($B) by Application (2027-2035)
• Figure 7.8: Trends and Forecast for the United States Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 7.9: Trends and Forecast for the Mexican Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 7.10: Trends and Forecast for the Canadian Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 8.1: Trends and Forecast for the European Neuromyelitis Optica Drug Market (2019-2035)
• Figure 8.2: European Neuromyelitis Optica Drug Market by Type in 2019, 2026, and 2035
• Figure 8.3: Trends of the European Neuromyelitis Optica Drug Market ($B) by Type (2019-2026)
• Figure 8.4: Forecast for the European Neuromyelitis Optica Drug Market ($B) by Type (2027-2035)
• Figure 8.5: European Neuromyelitis Optica Drug Market by Application in 2019, 2026, and 2035
• Figure 8.6: Trends of the European Neuromyelitis Optica Drug Market ($B) by Application (2019-2026)
• Figure 8.7: Forecast for the European Neuromyelitis Optica Drug Market ($B) by Application (2027-2035)
• Figure 8.8: Trends and Forecast for the German Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 8.9: Trends and Forecast for the French Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 8.10: Trends and Forecast for the Spanish Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 8.11: Trends and Forecast for the Italian Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 8.12: Trends and Forecast for the United Kingdom Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 9.1: Trends and Forecast for the APAC Neuromyelitis Optica Drug Market (2019-2035)
• Figure 9.2: APAC Neuromyelitis Optica Drug Market by Type in 2019, 2026, and 2035
• Figure 9.3: Trends of the APAC Neuromyelitis Optica Drug Market ($B) by Type (2019-2026)
• Figure 9.4: Forecast for the APAC Neuromyelitis Optica Drug Market ($B) by Type (2027-2035)
• Figure 9.5: APAC Neuromyelitis Optica Drug Market by Application in 2019, 2026, and 2035
• Figure 9.6: Trends of the APAC Neuromyelitis Optica Drug Market ($B) by Application (2019-2026)
• Figure 9.7: Forecast for the APAC Neuromyelitis Optica Drug Market ($B) by Application (2027-2035)
• Figure 9.8: Trends and Forecast for the Japanese Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 9.9: Trends and Forecast for the Indian Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 9.10: Trends and Forecast for the Chinese Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 9.11: Trends and Forecast for the South Korean Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 9.12: Trends and Forecast for the Indonesian Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 10.1: Trends and Forecast for the ROW Neuromyelitis Optica Drug Market (2019-2035)
• Figure 10.2: ROW Neuromyelitis Optica Drug Market by Type in 2019, 2026, and 2035
• Figure 10.3: Trends of the ROW Neuromyelitis Optica Drug Market ($B) by Type (2019-2026)
• Figure 10.4: Forecast for the ROW Neuromyelitis Optica Drug Market ($B) by Type (2027-2035)
• Figure 10.5: ROW Neuromyelitis Optica Drug Market by Application in 2019, 2026, and 2035
• Figure 10.6: Trends of the ROW Neuromyelitis Optica Drug Market ($B) by Application (2019-2026)
• Figure 10.7: Forecast for the ROW Neuromyelitis Optica Drug Market ($B) by Application (2027-2035)
• Figure 10.8: Trends and Forecast for the Middle Eastern Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 10.9: Trends and Forecast for the South American Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 10.10: Trends and Forecast for the African Neuromyelitis Optica Drug Market ($B) (2019-2035)
• Figure 11.1: Porter's Five Forces Analysis of the Global Neuromyelitis Optica Drug Market
• Figure 11.2: Market Share (%) of Top Players in the Global Neuromyelitis Optica Drug Market (2026)
• Figure 12.1: Growth Opportunities for the Global Neuromyelitis Optica Drug Market by Type
• Figure 12.2: Growth Opportunities for the Global Neuromyelitis Optica Drug Market by Application
• Figure 12.3: Growth Opportunities for the Global Neuromyelitis Optica Drug Market by Region
• Figure 12.4: Emerging Trends in the Global Neuromyelitis Optica Drug Market

List of Tables

• Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Neuromyelitis Optica Drug Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Neuromyelitis Optica Drug Market by Region
• Table 1.3: Global Neuromyelitis Optica Drug Market Parameters and Attributes
• Table 3.1: Trends of the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 3.2: Forecast for the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 4.1: Attractiveness Analysis for the Global Neuromyelitis Optica Drug Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 4.3: Market Size and CAGR of Various Type in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 4.4: Trends of Glucocorticoids in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 4.5: Forecast for Glucocorticoids in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 4.6: Trends of Immunotherapies in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 4.7: Forecast for Immunotherapies in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 4.8: Trends of Others in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 4.9: Forecast for Others in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 5.1: Attractiveness Analysis for the Global Neuromyelitis Optica Drug Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 5.3: Market Size and CAGR of Various Application in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 5.4: Trends of Acute Attack in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 5.5: Forecast for Acute Attack in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 5.6: Trends of Remission Prophylactic Treatment in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 5.7: Forecast for Remission Prophylactic Treatment in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Neuromyelitis Optica Drug Market (2019-2026)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Neuromyelitis Optica Drug Market (2027-2035)
• Table 7.1: Trends of the North American Neuromyelitis Optica Drug Market (2019-2026)
• Table 7.2: Forecast for the North American Neuromyelitis Optica Drug Market (2027-2035)
• Table 7.3: Market Size and CAGR of Various Type in the North American Neuromyelitis Optica Drug Market (2019-2026)
• Table 7.4: Market Size and CAGR of Various Type in the North American Neuromyelitis Optica Drug Market (2027-2035)
• Table 7.5: Market Size and CAGR of Various Application in the North American Neuromyelitis Optica Drug Market (2019-2026)
• Table 7.6: Market Size and CAGR of Various Application in the North American Neuromyelitis Optica Drug Market (2027-2035)
• Table 7.7: Trends and Forecast for the United States Neuromyelitis Optica Drug Market (2019-2035)
• Table 7.8: Trends and Forecast for the Mexican Neuromyelitis Optica Drug Market (2019-2035)
• Table 7.9: Trends and Forecast for the Canadian Neuromyelitis Optica Drug Market (2019-2035)
• Table 8.1: Trends of the European Neuromyelitis Optica Drug Market (2019-2026)
• Table 8.2: Forecast for the European Neuromyelitis Optica Drug Market (2027-2035)
• Table 8.3: Market Size and CAGR of Various Type in the European Neuromyelitis Optica Drug Market (2019-2026)
• Table 8.4: Market Size and CAGR of Various Type in the European Neuromyelitis Optica Drug Market (2027-2035)
• Table 8.5: Market Size and CAGR of Various Application in the European Neuromyelitis Optica Drug Market (2019-2026)
• Table 8.6: Market Size and CAGR of Various Application in the European Neuromyelitis Optica Drug Market (2027-2035)
• Table 8.7: Trends and Forecast for the German Neuromyelitis Optica Drug Market (2019-2035)
• Table 8.8: Trends and Forecast for the French Neuromyelitis Optica Drug Market (2019-2035)
• Table 8.9: Trends and Forecast for the Spanish Neuromyelitis Optica Drug Market (2019-2035)
• Table 8.10: Trends and Forecast for the Italian Neuromyelitis Optica Drug Market (2019-2035)
• Table 8.11: Trends and Forecast for the United Kingdom Neuromyelitis Optica Drug Market (2019-2035)
• Table 9.1: Trends of the APAC Neuromyelitis Optica Drug Market (2019-2026)
• Table 9.2: Forecast for the APAC Neuromyelitis Optica Drug Market (2027-2035)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Neuromyelitis Optica Drug Market (2019-2026)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Neuromyelitis Optica Drug Market (2027-2035)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Neuromyelitis Optica Drug Market (2019-2026)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Neuromyelitis Optica Drug Market (2027-2035)
• Table 9.7: Trends and Forecast for the Japanese Neuromyelitis Optica Drug Market (2019-2035)
• Table 9.8: Trends and Forecast for the Indian Neuromyelitis Optica Drug Market (2019-2035)
• Table 9.9: Trends and Forecast for the Chinese Neuromyelitis Optica Drug Market (2019-2035)
• Table 9.10: Trends and Forecast for the South Korean Neuromyelitis Optica Drug Market (2019-2035)
• Table 9.11: Trends and Forecast for the Indonesian Neuromyelitis Optica Drug Market (2019-2035)
• Table 10.1: Trends of the ROW Neuromyelitis Optica Drug Market (2019-2026)
• Table 10.2: Forecast for the ROW Neuromyelitis Optica Drug Market (2027-2035)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Neuromyelitis Optica Drug Market (2019-2026)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Neuromyelitis Optica Drug Market (2027-2035)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Neuromyelitis Optica Drug Market (2019-2026)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Neuromyelitis Optica Drug Market (2027-2035)
• Table 10.7: Trends and Forecast for the Middle Eastern Neuromyelitis Optica Drug Market (2019-2035)
• Table 10.8: Trends and Forecast for the South American Neuromyelitis Optica Drug Market (2019-2035)
• Table 10.9: Trends and Forecast for the African Neuromyelitis Optica Drug Market (2019-2035)
• Table 11.1: Product Mapping of Neuromyelitis Optica Drug Suppliers Based on Segments
• Table 11.2: Operational Integration of Neuromyelitis Optica Drug Manufacturers
• Table 11.3: Rankings of Suppliers Based on Neuromyelitis Optica Drug Revenue
• Table 12.1: New Product Launches by Major Neuromyelitis Optica Drug Producers (2019-2026)
• Table 12.2: Certification Acquired by Major Competitor in the Global Neuromyelitis Optica Drug Market